Jason B. Litten
Directeur Technique/Scientifique/R&D chez CHIMERIC THERAPEUTICS LIMITED
Profil
Jason B.
Litten is currently the Chief Medical Officer at Chimeric Therapeutics Ltd.
(Australia) and also holds the position of Chief Medical Officer at Optera Therapeutics Corp.
He previously worked as Vice President-Clinical Development at Clovis Oncology, Inc. and Juno Therapeutics, Inc. From 2019 to 2022, he served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. Litten holds a doctorate degree from Emory University and an undergraduate degree from Cornell University.
Postes actifs de Jason B. Litten
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Directeur Technique/Scientifique/R&D | 25/07/2022 |
| Optera Therapeutics Corp. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Jason B. Litten
| Sociétés | Poste | Fin |
|---|---|---|
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 06/06/2022 |
| CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | - |
Formation de Jason B. Litten
| Cornell University | Undergraduate Degree |
| Emory University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
| Optera Therapeutics Corp. | |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
